Breast Cancer
Conference Coverage
PFS Benefits Seen With Palbociclib + Endocrine Therapy in Breast Cancer
Palbociclib plus endocrine therapy or chemotherapy: Which is best in HR+/HER2- metastatic breast cancer?
Feature
New Canadian BC Guidelines Emphasize Personal Choice
The guidelines stem from a review of more than 165 recent randomized controlled trials, observational studies, mathematical models, and other data...
From the Journals
Should Cancer Trial Eligibility Become More Inclusive?
A new study highlights the potential benefits of broadening eligibility criteria for clinical trials.
Feature
New ADC results mixed in metastatic breast cancer
While T-DXd showed promise for yet another indication at ASCO, other findings underscored that much still remains to be learned about this drug...
From the Journals
Weight Loss Drugs Cut Cancer Risk in Diabetes Patients
Researchers examine electronic health records of patients who had type 2 diabetes, no prior diagnosis of obesity-related cancers, and had been...
Conference Coverage
Adjuvant Avelumab Benefits Seen in High Risk, Triple Negative BC
Researchers conduct first randomized phase 3 trial of patients with TNBC treated with adjuvant avelumab.
Conference Coverage
Clinical Controversy: Standard Dose or Baby TAM for Breast Cancer Prevention?
Docs debate which dose of tamoxifen is best for reducing breast cancer risk at the ESMO Breast Cancer Congress.
From the Journals
Urticaria Linked to Higher Cancer Risk, Study Finds
Researchers compare the incident cancer risk between patients with urticaria and the general population using data from Danish healthcare...
Feature
Time Warp: Fax Machines Still Common in Oncology Practice. Why?
Oncologists are among the many specialists across the country at the mercy of telecopiers.
Feature
Cancer Drug Shortages Continue in the US, Survey Finds
Not having enough of a significant spectrum of generic chemotherapies and supportive care medications is an ongoing issue, NCCN surveys suggest....
Conference Coverage
MUC-1 vaccine associated with notable overall survival rates in breast cancer
Patients with HER2-negative early breast cancer receive preoperative standard of care neoadjuvant treatment with or without tecemotide, in new...